Q-omics provides the consensus-scored TBX5 profile across patient tissues and cancer cell-line models. TBX5 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, TBX5 is differentially expressed in 11, with the highest sampling consensus in BLCA. Additionally, TBX5 RNA expression shows 13,594 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight SKCM, BLCA, and LSCC as cancer lineages where TBX5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TBX5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TBX5 survival associations across molecular data types. TBX5 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (6) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TBX5 RNA expression–survival associations across cancer types. High TBX5 expression shows unfavorable associations in BLCA, ACC, KIRC and LUSC, but favorable associations in SKCM and LUAD. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for TBX5 RNA expression.
This table summarizes TBX5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 3. The strongest signals are observed in LUAD for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for TBX5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TBX5 shows lower tumor expression in BLCA, LUAD, LUSC and THCA and higher tumor expression in COAD and HNSC. The BLCA box plot shows higher TBX5 RNA expression in normal versus tumor tissue (log2 FC = −3.365, t-test p < 0.001).
This table shows molecular features associated with TBX5 in patient tissues and cancer cell lines. In patient samples, TBX5 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, TBX5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in OVARY and BONE.
